BBC stock forecast, quote, news & analysis

The most notable companies in this group are Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX).

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

The average market capitalization across the Virtus LifeSci Biotech Clinical Trls ETF ETF is 1.97B. The market cap for tickers in the group ranges from 37.41M to 13.73B. SMMT holds the highest valuation in this group at 13.73B. The lowest valued company is RAPT at 37.41M.

The average weekly price growth across all stocks in the Virtus LifeSci Biotech Clinical Trls ETF ETF was -8%. For the same ETF, the average monthly price growth was -13%, and the average quarterly price growth was -1%. SAVA experienced the highest price growth at 23%, while CABA experienced the biggest fall at -51%.

The average weekly volume growth across all stocks in the Virtus LifeSci Biotech Clinical Trls ETF ETF was -0%. For the same stocks of the ETF, the average monthly volume growth was 53% and the average quarterly volume growth was 30%